DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.
You may also be interested in...
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
